CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Seres Therapeutics Inc - MCRB CFD

    1.06
    3.64%
    0.05
    Low: 1.05
    High: 1.08
    Market Trading Hours* (UTC) Open now
    Closes on Tuesday at 21:00

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026346 %
    Charges from full value of position ($-5.01)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026346%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004124 %
    Charges from full value of position ($0.78)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004124%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Seres Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.1
    Open* 1.06
    1-Year Change* -85.07%
    Day's Range* 1.05 - 1.08
    52 wk Range 0.91-7.30
    Average Volume (10 days) 3.96M
    Average Volume (3 months) 73.54M
    Market Cap 135.07M
    P/E Ratio -100.00K
    Shares Outstanding 129.26M
    Revenue 127.24M
    EPS -1.13
    Dividend (Yield %) N/A
    Beta 2.52
    Next Earnings Date Mar 5, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 4, 2023 1.10 0.05 4.76% 1.05 1.12 1.02
    Dec 1, 2023 1.04 0.05 5.05% 0.99 1.06 0.96
    Nov 30, 2023 1.03 -0.08 -7.21% 1.11 1.13 0.99
    Nov 29, 2023 1.09 -0.02 -1.80% 1.11 1.18 1.09
    Nov 28, 2023 1.10 -0.02 -1.79% 1.12 1.13 1.08
    Nov 27, 2023 1.13 0.05 4.63% 1.08 1.14 1.04
    Nov 24, 2023 1.12 0.05 4.67% 1.07 1.17 1.07
    Nov 22, 2023 1.08 0.03 2.86% 1.05 1.10 0.98
    Nov 21, 2023 1.02 -0.04 -3.77% 1.06 1.15 1.01
    Nov 20, 2023 0.95 -0.43 -31.16% 1.38 1.38 0.94
    Nov 17, 2023 1.39 0.23 19.83% 1.16 1.41 1.14
    Nov 16, 2023 1.14 -0.05 -4.20% 1.19 1.20 1.09
    Nov 15, 2023 1.18 -0.01 -0.84% 1.19 1.33 1.18
    Nov 14, 2023 1.21 0.16 15.24% 1.05 1.21 1.05
    Nov 13, 2023 1.04 0.04 4.00% 1.00 1.05 0.96
    Nov 10, 2023 0.99 0.02 2.06% 0.97 0.99 0.94
    Nov 9, 2023 0.98 -0.05 -4.85% 1.03 1.03 0.90
    Nov 8, 2023 1.01 -0.18 -15.13% 1.19 1.19 1.00
    Nov 7, 2023 1.19 0.06 5.31% 1.13 1.20 1.05
    Nov 6, 2023 1.11 -0.17 -13.28% 1.28 1.30 1.11

    Seres Therapeutics Inc Events

    Time (UTC) Country Event
    Tuesday, March 5, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Seres Therapeutics Inc Earnings Release
    Q4 2023 Seres Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 7.128 144.927 33.215 34.505 28.267
    Revenue 7.128 144.927 33.215 34.505 28.267
    Total Operating Expense 253.618 209.42 121.345 106.381 128.551
    Selling/General/Admin. Expenses, Total 85.796 69.261 30.775 24.748 32.596
    Research & Development 166.818 141.891 90.57 80.141 95.955
    Operating Income -246.49 -64.493 -88.13 -71.876 -100.284
    Interest Income (Expense), Net Non-Operating -2.962 -0.04 -1.978 0.531 1.172
    Net Income Before Taxes -250.157 -65.578 -89.127 -70.279 -98.942
    Net Income After Taxes -250.157 -65.578 -89.127 -70.279 -98.942
    Net Income Before Extra. Items -250.157 -65.578 -89.127 -70.279 -98.942
    Net Income -250.157 -65.578 -89.127 -70.279 -98.942
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -250.157 -65.578 -89.127 -70.279 -98.942
    Income Available to Common Incl. Extra. Items -250.157 -65.578 -89.127 -70.279 -98.942
    Diluted Net Income -250.157 -65.578 -89.127 -70.279 -98.942
    Diluted Weighted Average Shares 108.077 91.7029 79.7892 56.6492 40.7435
    Diluted EPS Excluding Extraordinary Items -2.31462 -0.71511 -1.11703 -1.2406 -2.42841
    Diluted Normalized EPS -2.31462 -0.71511 -1.11703 -1.21426 -2.42841
    Other, Net -0.705 -1.045 0.981 1.066 0.17
    Total Extraordinary Items 0
    Dividends per Share - Common Stock Primary Issue
    Unusual Expense (Income) 0 0 1.492
    Other Operating Expenses, Total 1.004 -1.732
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 126.473 -0.522 0.975 3.444 1.216
    Revenue 126.473 -0.522 0.975 3.444 1.216
    Total Operating Expense 76.949 70.046 69.282 62.551 64.541
    Selling/General/Admin. Expenses, Total 28.051 22.47 22.404 18.384 20.335
    Research & Development 46.792 43.969 46.22 43.116 43.935
    Operating Income 49.524 -70.568 -68.307 -59.107 -63.325
    Interest Income (Expense), Net Non-Operating -1.461 -0.916 -0.466 -0.862 -1.106
    Other, Net -1.511 0.31 -0.023 -0.033 -0.304
    Net Income Before Taxes 46.552 -71.174 -68.796 -60.002 -64.735
    Net Income After Taxes 46.552 -71.174 -68.796 -60.002 -64.735
    Net Income Before Extra. Items 46.552 -71.174 -68.796 -60.002 -64.735
    Net Income 46.552 -71.174 -68.796 -60.002 -64.735
    Income Available to Common Excl. Extra. Items 46.552 -71.174 -68.796 -60.002 -64.735
    Income Available to Common Incl. Extra. Items 46.552 -71.174 -68.796 -60.002 -64.735
    Diluted Net Income 46.552 -71.174 -68.796 -60.002 -64.735
    Diluted Weighted Average Shares 129.845 125.863 125.166 122.527 92.2554
    Diluted EPS Excluding Extraordinary Items 0.35852 -0.56549 -0.54964 -0.4897 -0.70169
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS 0.35852 -0.56549 -0.54964 -0.4897 -0.70169
    Other Operating Expenses, Total 2.106 3.607 0.658 1.051 0.271
    Unusual Expense (Income)
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 194.764 303.628 268.777 100.189 92.665
    Cash and Short Term Investments 181.341 290.706 253.616 94.816 85.82
    Cash & Equivalents 163.03 180.002 116.049 65.126 85.82
    Short Term Investments 18.311 110.704 137.567 29.69 0
    Prepaid Expenses 13.423 12.922 5.774 3.588 6.845
    Total Assets 348.784 354.859 342.94 132.44 120.472
    Property/Plant/Equipment, Total - Net 133.969 36.146 22.938 30.851 26.294
    Property/Plant/Equipment, Total - Gross 179.009 76.414 57.258 58.593 46.595
    Accumulated Depreciation, Total -45.04 -40.268 -34.32 -27.742 -20.301
    Long Term Investments 0 0.495 49.825
    Other Long Term Assets, Total 20.051 14.59 1.4 1.4 1.513
    Total Current Liabilities 85.596 82.258 46.415 45.993 42.041
    Accounts Payable 17.44 13.735 4.018 4.859 6.415
    Accrued Expenses 18.31 15.826 11.849 9.065 5.02
    Notes Payable/Short Term Debt 0.456 0 0.454 0 0
    Other Current Liabilities, Total 49.39 52.697 30.094 32.069 30.606
    Total Liabilities 338.001 223.352 168.19 180.764 168.517
    Total Long Term Debt 50.591 24.643 24.639 24.648 0
    Other Liabilities, Total 201.814 116.451 97.136 110.123 126.476
    Total Equity 10.783 131.507 174.75 -48.324 -48.045
    Common Stock 0.125 0.092 0.091 0.07 0.041
    Additional Paid-In Capital 875.181 745.829 723.482 411.255 341.284
    Retained Earnings (Accumulated Deficit) -864.511 -614.354 -548.776 -459.649 -389.37
    Other Equity, Total -0.012 -0.06 -0.047 0
    Total Liabilities & Shareholders’ Equity 348.784 354.859 342.94 132.44 120.472
    Total Common Shares Outstanding 125.222 91.8894 91.4592 70.1432 40.9367
    Redeemable Preferred Stock
    Total Receivables, Net 0 9.387 1.785
    Accounts Receivable - Trade, Net 0 9.387 1.785
    Long Term Debt 50.591 24.643 24.639 24.648
    Current Port. of LT Debt/Capital Leases 0
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 214.394 251.238 116.081 194.764 247.513
    Cash and Short Term Investments 169.912 229.52 106.544 181.341 233.003
    Cash & Equivalents 169.912 229.52 94.841 163.03 205.398
    Short Term Investments 0 0 11.703 18.311 27.605
    Total Receivables, Net 16.857 7.559
    Accounts Receivable - Trade, Net
    Prepaid Expenses 9.1 8.819 9.537 13.423 14.51
    Total Assets 367.699 406.387 270.194 348.784 311.868
    Property/Plant/Equipment, Total - Net 131.671 134.309 133.22 133.969 43.231
    Property/Plant/Equipment, Total - Gross 181.322 182.276 179.66 179.009 88.501
    Accumulated Depreciation, Total -49.651 -47.967 -46.44 -45.04 -45.27
    Long Term Investments 0 0
    Other Long Term Assets, Total 21.634 20.84 20.893 20.051 21.124
    Total Current Liabilities 79.225 77.898 63.818 85.596 81.819
    Accounts Payable 8.958 12.922 12.297 17.44 10.449
    Accrued Expenses 19.759 17.158 11.661 18.31 18.114
    Notes Payable/Short Term Debt 0 0 0 0.456 0
    Current Port. of LT Debt/Capital Leases
    Other Current Liabilities, Total 50.508 47.818 39.86 49.39 53.256
    Total Liabilities 382.822 383.773 318.065 338.001 244.283
    Total Long Term Debt 101.135 100.742 51.234 50.591 50.857
    Long Term Debt 101.135 100.742 51.234 50.591 50.857
    Other Liabilities, Total 202.462 205.133 203.013 201.814 111.607
    Total Equity -15.123 22.614 -47.871 10.783 67.585
    Common Stock 0.129 0.128 0.127 0.125 0.124
    Additional Paid-In Capital 921.735 911.62 887.685 875.181 863.294
    Retained Earnings (Accumulated Deficit) -936.987 -889.133 -935.685 -864.511 -795.715
    Other Equity, Total 0 -0.001 0.002 -0.012 -0.118
    Total Liabilities & Shareholders’ Equity 367.699 406.387 270.194 348.784 311.868
    Total Common Shares Outstanding 128.631 128.038 126.593 125.222 124.411
    Total Inventory 18.525 5.34
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -250.157 -65.578 -89.127 -70.279 -98.942
    Cash From Operating Activities -228.815 6.688 -93.61 -76.52 -62.854
    Cash From Operating Activities 6.629 5.947 6.578 7.603 7.862
    Non-Cash Items 33.103 24.789 12.136 10.783 16.427
    Cash Interest Paid 4.926 2.446 2.453 0.221 0
    Changes in Working Capital -18.39 41.53 -23.197 -24.627 11.799
    Cash From Investing Activities 82.428 64.088 -158.891 -30.518 112.318
    Capital Expenditures -9.821 -9.566 -0.591 -1.002 -1.937
    Other Investing Cash Flow Items, Total 92.249 73.654 -158.3 -29.516 114.255
    Cash From Financing Activities 129.602 1.178 303.424 86.231 0.268
    Issuance (Retirement) of Stock, Net 103.903 2.126 283.524 61.656 0.268
    Net Change in Cash -16.786 71.953 50.923 -20.807 49.732
    Financing Cash Flow Items 0 19.9 -0.425
    Issuance (Retirement) of Debt, Net 25.699 -0.948 25
    Foreign Exchange Effects -0.001 -0.001
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -71.174 -250.157 -181.361 -121.359 -56.624
    Cash From Operating Activities -76.584 -228.815 -175.922 -116.342 -66.445
    Cash From Operating Activities 1.4 6.629 5.002 3.255 1.57
    Non-Cash Items 12.527 33.103 23.324 14.302 5.607
    Cash Interest Paid 1.737 4.926 3.282 1.836 0.558
    Changes in Working Capital -19.337 -18.39 -22.887 -12.54 -16.998
    Cash From Investing Activities 2.739 82.428 76.502 36.371 12.972
    Capital Expenditures -4.068 -9.821 -6.36 -5.113 -2.95
    Other Investing Cash Flow Items, Total 6.807 92.249 82.862 41.484 15.922
    Cash From Financing Activities 5.656 129.602 125.005 26.978 26.848
    Issuance (Retirement) of Stock, Net 5.656 103.903 102.585 1.279 1.149
    Net Change in Cash -68.189 -16.786 25.583 -52.993 -26.625
    Financing Cash Flow Items -3.279
    Issuance (Retirement) of Debt, Net 0 25.699 25.699 25.699 25.699
    Foreign Exchange Effects -0.001 -0.002
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Flagship Ventures Venture Capital 18.0314 23117045 0 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 14.9645 19185208 273750 2023-06-30 LOW
    Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 8.888 11394801 -105719 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 6.6807 8564935 4796626 2023-06-30 LOW
    Nestle SA Corporation 5.9234 7594038 -298852 2022-07-18 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.2306 6705853 1327621 2023-06-30 LOW
    Janus Henderson Investors Investment Advisor/Hedge Fund 4.7369 6072942 -5227873 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.1596 5332847 -505131 2023-06-30 LOW
    Eversept Partners, LP Hedge Fund 2.3999 3076756 540091 2023-06-30 HIGH
    Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 1.95 2500000 1205000 2023-06-30 LOW
    Soleus Capital Management, L.P. Hedge Fund 1.5959 2045983 2045983 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.5299 1961358 325849 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 1.3727 1759914 1351434 2023-06-30 HIGH
    Jennison Associates LLC Investment Advisor/Hedge Fund 1.086 1392356 727622 2023-06-30 LOW
    BofA Global Research (US) Research Firm 0.9312 1193896 810048 2023-06-30 LOW
    Point72 Asset Management, L.P. Hedge Fund 0.7959 1020400 727600 2023-06-30 HIGH
    Handelsbanken Kapitalförvaltning AB Investment Advisor/Hedge Fund 0.78 1000000 0 2023-09-30 LOW
    Great Point Partners, LLC Hedge Fund 0.7317 938067 938067 2023-06-30 HIGH
    Hudson Bay Capital Management LP Hedge Fund 0.6864 880000 355000 2023-06-30 HIGH
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.6183 792699 160286 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Seres Therapeutics Inc Company profile

    About Seres Therapeutics Inc

    Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis and SER-155 to treat enteric bacterial pathogens.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Seres Therapeutics Inc revenues increased from $33.2M to $144.9M. Net loss decreased 26% to $65.6M. Revenues reflect Collaboration revenue - related party increase from $11.9M to $143.9M. Lower net loss reflects Interest income increase from $946K to $2.9M (income), Interest expense remaining flat at $2.9M (expense).

    Industry: Bio Therapeutic Drugs

    200 Sidney St
    CAMBRIDGE
    MASSACHUSETTS 02139-4218
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    72.79 Price
    -0.810% 1D Chg, %
    Long position overnight fee -0.0224%
    Short position overnight fee 0.0005%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Gold

    2,019.85 Price
    -0.550% 1D Chg, %
    Long position overnight fee -0.0200%
    Short position overnight fee 0.0118%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    BTC/USD

    43,668.25 Price
    +3.830% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    15,857.50 Price
    +0.130% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading